Effect of thoracic radiotherapy on mortality in limited small cell lung cancer. A meta-analysis of 13 randomized trials among 2,140 patients

R. Arriagada, J. P. Pignon, D. C. Ihde, D. H. Johnson, M. C. Perry, R. L. Souhami, O. Brodin, R. A. Joss, M. S. Kies, B. Lebeau, T. Onoshi, K. Osterlind, M. H N Tattersall, H. Wagner

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

This meta-analysis was designed to evaluate the hypothesis that thoracic radiotherapy contributes to a moderate increase in overall survival in limited small-cell lung cancer. We collected individual data on all patients enrolled before December 1988 in randomized trials comparing chemotherapy alone with chemotherapy combined with thoracic radiotherapy. The study included 13 trials and 2140 patients with limited disease. A total of 433 patient with extensive disease were excluded. Overall, 1862 of 2103 patients who could be evaluated died; the median follow-up period for the surviving patients was 43 months. The relative risk of death in the combined therapy group as compared with the chemotherapy group was 0.86 (95 percent confidence interval, 0.78 to 0.94 P = 0.001), corresponding to a 14 percent reduction in the mortality rate. The benefit in terms of overall survival at three years (±SD) wins 5.4 ± 1.4 percent. Indirect comparison of early with late radiotherapy and of sequential with nonsequential radiotherapy did not reveal any optimal time for treatment. There was a trend toward a larger reduction in mortality among younger patients. In conclusion, thoracic radiotherapy moderately improves overall survival in patients with limited small-cell lung cancer who are treated with combination chemotherapy.

Original languageEnglish (US)
Pages (from-to)333-335
Number of pages3
JournalAnticancer Research
Volume14
Issue number1 B
StatePublished - 1994

Fingerprint

Small Cell Lung Carcinoma
Meta-Analysis
Radiotherapy
Thorax
Mortality
Drug Therapy
Survival
Group Psychotherapy
Combination Drug Therapy
Confidence Intervals

Keywords

  • Randomized trial
  • Small cell lung cancer
  • Survival meta-analysis
  • Thoracic radiotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Arriagada, R., Pignon, J. P., Ihde, D. C., Johnson, D. H., Perry, M. C., Souhami, R. L., ... Wagner, H. (1994). Effect of thoracic radiotherapy on mortality in limited small cell lung cancer. A meta-analysis of 13 randomized trials among 2,140 patients. Anticancer Research, 14(1 B), 333-335.

Effect of thoracic radiotherapy on mortality in limited small cell lung cancer. A meta-analysis of 13 randomized trials among 2,140 patients. / Arriagada, R.; Pignon, J. P.; Ihde, D. C.; Johnson, D. H.; Perry, M. C.; Souhami, R. L.; Brodin, O.; Joss, R. A.; Kies, M. S.; Lebeau, B.; Onoshi, T.; Osterlind, K.; Tattersall, M. H N; Wagner, H.

In: Anticancer Research, Vol. 14, No. 1 B, 1994, p. 333-335.

Research output: Contribution to journalArticle

Arriagada, R, Pignon, JP, Ihde, DC, Johnson, DH, Perry, MC, Souhami, RL, Brodin, O, Joss, RA, Kies, MS, Lebeau, B, Onoshi, T, Osterlind, K, Tattersall, MHN & Wagner, H 1994, 'Effect of thoracic radiotherapy on mortality in limited small cell lung cancer. A meta-analysis of 13 randomized trials among 2,140 patients', Anticancer Research, vol. 14, no. 1 B, pp. 333-335.
Arriagada, R. ; Pignon, J. P. ; Ihde, D. C. ; Johnson, D. H. ; Perry, M. C. ; Souhami, R. L. ; Brodin, O. ; Joss, R. A. ; Kies, M. S. ; Lebeau, B. ; Onoshi, T. ; Osterlind, K. ; Tattersall, M. H N ; Wagner, H. / Effect of thoracic radiotherapy on mortality in limited small cell lung cancer. A meta-analysis of 13 randomized trials among 2,140 patients. In: Anticancer Research. 1994 ; Vol. 14, No. 1 B. pp. 333-335.
@article{f2b9fcf871a74ac2a447585434764911,
title = "Effect of thoracic radiotherapy on mortality in limited small cell lung cancer. A meta-analysis of 13 randomized trials among 2,140 patients",
abstract = "This meta-analysis was designed to evaluate the hypothesis that thoracic radiotherapy contributes to a moderate increase in overall survival in limited small-cell lung cancer. We collected individual data on all patients enrolled before December 1988 in randomized trials comparing chemotherapy alone with chemotherapy combined with thoracic radiotherapy. The study included 13 trials and 2140 patients with limited disease. A total of 433 patient with extensive disease were excluded. Overall, 1862 of 2103 patients who could be evaluated died; the median follow-up period for the surviving patients was 43 months. The relative risk of death in the combined therapy group as compared with the chemotherapy group was 0.86 (95 percent confidence interval, 0.78 to 0.94 P = 0.001), corresponding to a 14 percent reduction in the mortality rate. The benefit in terms of overall survival at three years (±SD) wins 5.4 ± 1.4 percent. Indirect comparison of early with late radiotherapy and of sequential with nonsequential radiotherapy did not reveal any optimal time for treatment. There was a trend toward a larger reduction in mortality among younger patients. In conclusion, thoracic radiotherapy moderately improves overall survival in patients with limited small-cell lung cancer who are treated with combination chemotherapy.",
keywords = "Randomized trial, Small cell lung cancer, Survival meta-analysis, Thoracic radiotherapy",
author = "R. Arriagada and Pignon, {J. P.} and Ihde, {D. C.} and Johnson, {D. H.} and Perry, {M. C.} and Souhami, {R. L.} and O. Brodin and Joss, {R. A.} and Kies, {M. S.} and B. Lebeau and T. Onoshi and K. Osterlind and Tattersall, {M. H N} and H. Wagner",
year = "1994",
language = "English (US)",
volume = "14",
pages = "333--335",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "1 B",

}

TY - JOUR

T1 - Effect of thoracic radiotherapy on mortality in limited small cell lung cancer. A meta-analysis of 13 randomized trials among 2,140 patients

AU - Arriagada, R.

AU - Pignon, J. P.

AU - Ihde, D. C.

AU - Johnson, D. H.

AU - Perry, M. C.

AU - Souhami, R. L.

AU - Brodin, O.

AU - Joss, R. A.

AU - Kies, M. S.

AU - Lebeau, B.

AU - Onoshi, T.

AU - Osterlind, K.

AU - Tattersall, M. H N

AU - Wagner, H.

PY - 1994

Y1 - 1994

N2 - This meta-analysis was designed to evaluate the hypothesis that thoracic radiotherapy contributes to a moderate increase in overall survival in limited small-cell lung cancer. We collected individual data on all patients enrolled before December 1988 in randomized trials comparing chemotherapy alone with chemotherapy combined with thoracic radiotherapy. The study included 13 trials and 2140 patients with limited disease. A total of 433 patient with extensive disease were excluded. Overall, 1862 of 2103 patients who could be evaluated died; the median follow-up period for the surviving patients was 43 months. The relative risk of death in the combined therapy group as compared with the chemotherapy group was 0.86 (95 percent confidence interval, 0.78 to 0.94 P = 0.001), corresponding to a 14 percent reduction in the mortality rate. The benefit in terms of overall survival at three years (±SD) wins 5.4 ± 1.4 percent. Indirect comparison of early with late radiotherapy and of sequential with nonsequential radiotherapy did not reveal any optimal time for treatment. There was a trend toward a larger reduction in mortality among younger patients. In conclusion, thoracic radiotherapy moderately improves overall survival in patients with limited small-cell lung cancer who are treated with combination chemotherapy.

AB - This meta-analysis was designed to evaluate the hypothesis that thoracic radiotherapy contributes to a moderate increase in overall survival in limited small-cell lung cancer. We collected individual data on all patients enrolled before December 1988 in randomized trials comparing chemotherapy alone with chemotherapy combined with thoracic radiotherapy. The study included 13 trials and 2140 patients with limited disease. A total of 433 patient with extensive disease were excluded. Overall, 1862 of 2103 patients who could be evaluated died; the median follow-up period for the surviving patients was 43 months. The relative risk of death in the combined therapy group as compared with the chemotherapy group was 0.86 (95 percent confidence interval, 0.78 to 0.94 P = 0.001), corresponding to a 14 percent reduction in the mortality rate. The benefit in terms of overall survival at three years (±SD) wins 5.4 ± 1.4 percent. Indirect comparison of early with late radiotherapy and of sequential with nonsequential radiotherapy did not reveal any optimal time for treatment. There was a trend toward a larger reduction in mortality among younger patients. In conclusion, thoracic radiotherapy moderately improves overall survival in patients with limited small-cell lung cancer who are treated with combination chemotherapy.

KW - Randomized trial

KW - Small cell lung cancer

KW - Survival meta-analysis

KW - Thoracic radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=0028278911&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028278911&partnerID=8YFLogxK

M3 - Article

VL - 14

SP - 333

EP - 335

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 1 B

ER -